Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Insmed	Legend Biotech	Turning Point Therapeutics	Nektar Therapeutics	Apellis Pharmaceuticals
Symbol	NASDAQ:INSM	NASDAQ:LEGN	NASDAQ:TPTX	NASDAQ:NKTR	NASDAQ:APLS
Price Information
Current Price	$26.23	$29.60	$69.35	$18.98	$44.26
52 Week Range	Buy	Buy	Buy	Hold	Buy
MarketRank™
Overall Score	1.2	1.3	1.7	1.5	1.6
Analysis Score	3.5	3.5	3.5	3.0	3.4
Community Score	2.5	2.3	3.1	3.0	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	1.7	1.7	1.7
Earnings & Valuation Score	0.0	0.6	0.0	0.0	0.0
Analyst Ratings
Consensus Recommendation	Buy	Buy	Buy	Hold	Buy
Consensus Price Target	$53.57	$49.00	$153.71	$25.00	$130.08
% Upside from Price Target	104.24% upside	65.54% upside	121.65% upside	31.72% upside	193.89% upside
Trade Information
Market Cap	$2.64 billion	$4.13 billion	$3.36 billion	$3.44 billion	$3.67 billion
Beta	2.43	N/A	1.23	1.76	1.47
Average Volume	1,120,897	375,689	383,194	1,171,247	654,707
Sales & Book Value
Annual Revenue	$136.47 million	$64.39 million	N/A	$114.62 million	N/A
Price / Sales	19.89	61.14	N/A	30.19	N/A
Cashflow	N/A	N/A	N/A	N/A	N/A
Price / Cash	N/A	N/A	N/A	N/A	N/A
Book Value	$2.93 per share	N/A	$11.28 per share	$7.99 per share	$0.46 per share
Price / Book	8.95	∞	N/A	2.38	N/A
Profitability
Net Income	$-254,340,000.00	$-132,970,000.00	$-72,130,000.00	$-440,670,000.00	$-304,710,000.00
EPS	($3.01)	N/A	($2.99)	($2.52)	($4.64)
Trailing P/E Ratio	N/A	0.00	N/A	N/A	N/A
Forward P/E Ratio	N/A	N/A	N/A	N/A	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-145.14%	-543.73%	N/A	-269.05%	N/A
Return on Equity (ROE)	-79.58%	-205.60%	-23.81%	-30.74%	-336.93%
Return on Assets (ROA)	-31.14%	-43.03%	-23.08%	-22.63%	-78.28%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	1.03%	N/A	N/A	N/A	3.34%
Current Ratio	7.95%	4.88%	35.45%	8.25%	9.86%
Quick Ratio	7.43%	4.87%	35.45%	8.15%	9.86%
Ownership Information
Institutional Ownership Percentage	N/A	18.92%	81.31%	95.32%	81.20%
Insider Ownership Percentage	4.63%	N/A	23.20%	2.99%	9.50%
Miscellaneous
Employees	373	800	142	718	374
Shares Outstanding	103.49 million	133.01 million	49.16 million	182.31 million	80.50 million
Next Earnings Date	8/5/2021 (Estimated)	N/A	8/9/2021 (Estimated)	8/5/2021 (Estimated)	7/30/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	Apellis Pharmaceuticals (NASDAQ:APLS) Shares Down 3% americanbankingnews.com - May 14 at 1:11 PM
	Apellis to Present Long-Term Pegcetacoplan Data in PNH at the European Hematology Association ... apnews.com - May 12 at 1:11 PM
	Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $39.00 at Credit Suisse Group americanbankingnews.com - May 5 at 3:27 PM
	Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Analysts Are Reducing Their Forecasts For This Year finance.yahoo.com - May 4 at 7:45 AM
	Histogen (NASDAQ:HSTO) versus Apellis Pharmaceuticals (NASDAQ:APLS) Financial Comparison americanbankingnews.com - May 3 at 10:12 PM
	Insider Selling: Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) VP Sells 1,000 Shares of Stock americanbankingnews.com - May 3 at 8:18 PM
	Q2 2021 EPS Estimates for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Raised by Analyst americanbankingnews.com - May 3 at 2:48 AM
	Zacks: Analysts Anticipate Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Will Post Earnings of -$1.80 Per Share americanbankingnews.com - May 1 at 10:16 AM
	Is Apellis Pharmaceuticals (NASDAQ:APLS) Weighed On By Its Debt Load? finance.yahoo.com - May 1 at 9:37 AM
	Apellis Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation seekingalpha.com - April 30 at 4:50 PM
	Apellis Pharmaceuticals (NASDAQ:APLS) Releases Quarterly Earnings Results, Misses Estimates By $0.63 EPS americanbankingnews.com - April 29 at 3:20 PM
	Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 5.1% on Analyst Upgrade americanbankingnews.com - April 29 at 2:28 PM
	Apellis Pharmaceuticals (NASDAQ:APLS) PT Raised to $39.00 at Credit Suisse Group americanbankingnews.com - April 29 at 1:02 PM
	Apellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus finance.yahoo.com - April 29 at 12:41 PM
	Apellis Pharmaceuticals (NASDAQ:APLS) Given New $39.00 Price Target at Credit Suisse Group marketbeat.com - April 29 at 12:24 PM
	Analysts’ Opinions Are Mixed on These Healthcare Stocks: Boston Scientific (BSX) and Apellis Pharmaceuticals (APLS) smarteranalyst.com - April 29 at 7:41 AM
	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Apellis Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors finance.yahoo.com - April 26 at 9:34 AM
	Alec Machiels Sells 2,500 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock americanbankingnews.com - April 22 at 7:38 PM
	Apellis Pharmaceuticals (NASDAQ:APLS) Research Coverage Started at The Goldman Sachs Group americanbankingnews.com - April 22 at 8:32 AM
	Apellis Pharmaceuticals to Hold First Quarter 2021 Earnings Conference Call on April 28, 2021 finance.yahoo.com - April 21 at 8:15 AM
	Apellis to Showcase Leadership in Retina at Association for Research in Vision and ... apnews.com - April 16 at 5:34 PM
	Apellis Provides 24-Month Update from Phase 1b Study of Pegcetacoplan in Patients with ... apnews.com - April 13 at 1:02 PM
	Apellis Pharmaceuticals, Inc. (APLS) Down 7.9% Since Last Earnings Report: Can It Rebound? finance.yahoo.com - March 27 at 12:32 PM
	Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating ... apnews.com - March 10 at 2:31 PM
	Apellis Announces Two New Publications from the Positive Phase 2 FILLY Study Evaluating Pegcetacoplan in Geographic Atrophy finance.yahoo.com - March 10 at 9:31 AM
	Apellis stops COVID-19 program after missing mortality endpoint fiercebiotech.com - March 6 at 1:49 AM

Date	Company	Brokerage	Action
5/10/2021	Insmed	Morgan Stanley	Lower Price Target
1/19/2021	Insmed	Credit Suisse Group	Boost Price Target
1/4/2021	Insmed	SVB Leerink	Boost Price Target
12/17/2020	Insmed	Berenberg Bank	Initiated Coverage
11/23/2020	Insmed	Evercore ISI	Reiterated Rating
10/12/2020	Insmed	Stifel Nicolaus	Initiated Coverage
6/25/2020	Insmed	HC Wainwright	Reiterated Rating
2/4/2020	Insmed	The Goldman Sachs Group	Boost Price Target
1/15/2020	Insmed	JMP Securities	Reiterated Rating
1/6/2020	Insmed	Cowen	Reiterated Rating
1/2/2020	Insmed	Canaccord Genuity	Initiated Coverage
1/20/2021	Legend Biotech	JPMorgan Chase & Co.	Reiterated Rating
8/11/2020	Legend Biotech	Jefferies Financial Group	Reiterated Rating
4/6/2021	Turning Point Therapeutics	Roth Capital	Boost Price Target
4/6/2021	Turning Point Therapeutics	Oppenheimer	Reiterated Rating
10/26/2020	Turning Point Therapeutics	Wells Fargo & Company	Boost Price Target
5/7/2021	Nektar Therapeutics	Mizuho	Reiterated Rating
3/1/2021	Nektar Therapeutics	Benchmark	Reiterated Rating
6/10/2020	Nektar Therapeutics	Cfra	Downgrade
3/4/2020	Nektar Therapeutics	Barclays	Initiated Coverage
2/28/2020	Nektar Therapeutics	Piper Sandler	Reiterated Rating
2/28/2020	Nektar Therapeutics	BTIG Research	Lower Price Target
2/28/2020	Nektar Therapeutics	William Blair	Reiterated Rating
1/8/2021	Apellis Pharmaceuticals	Raymond James	Boost Price Target
12/1/2020	Apellis Pharmaceuticals	BMO Capital Markets	Boost Price Target
11/23/2020	Apellis Pharmaceuticals	Smith Barney Citigroup	Boost Price Target
11/23/2020	Apellis Pharmaceuticals	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Boost Price Target
11/19/2020	Apellis Pharmaceuticals	Needham & Company LLC	Initiated Coverage
10/9/2020	Apellis Pharmaceuticals	Cantor Fitzgerald	Reiterated Rating
5/28/2020	Apellis Pharmaceuticals	UBS Group	Initiated Coverage

(Data available from 5/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources